A. Gough et al., MEASUREMENT OF MARKERS OF OSTEOCLAST AND OSTEOBLAST ACTIVITY IN PATIENTS WITH ACUTE AND CHRONIC DIABETIC CHARCOT-NEUROARTHROPATHY, Diabetic medicine, 14(7), 1997, pp. 527-531
Excess osteoclast activity is believed to be responsible for the early
bone changes associated with Charcot neuroarthropathy in diabetes mel
litus. Markers of osteoclast and osteoblast activity were measured in
four groups of patients: 16 with an acute Charcot foot, 16 with a chro
nic Charcot foot, 10 diabetic controls, and 10 non-diabetic controls.
Serum carboxyterminal telopeptide of type 1 collagen (1CTP), a marker
of osteoclastic bone resorption, was significantly raised in the dorsa
l venous arch of the acute Charcot foot, 6.1 +/- 1.5 mu g l(-1) (mean
+/- SD) compared with the chronic Charcot foot 4.1 +/- 1.4, diabetic c
ontrols 3.3 +/- 1.4, and non-diabetic controls 2.8 +/- 1.4, p < 0.0001
. This local increase in 1CTP was also reflected systemically in a stu
dy subgroup of 6 patients with acute Charcot neuroarthropathy, in whom
peripheral antecubital vein 1CTP was 9.2 +/- 2.6 compared with 9.0 +/
- 3.1 in the foot. In 6 chronic Charcot neuroarthropathy patients, foo
t (3.8 +/- 1.3) and systemic (4.0 +/- 1.5) 1CTP values were similar. S
erum procollagen carboxyterminal propeptide (P1CP), an indicator of os
teoblastic bone formation, was not significantly different between the
feet of patients with acute Charcot neuroarthropathy 112 +/- 1.5 mu g
l(-1), patients with chronic Charcot neuroarthropathy 109 +/- 1.5 mu
g l(-1), diabetic controls 93.5 +/- 2.3 mu g l(-1), and non-diabetic c
ontrols 90.1 +/- 1.5 mu g l(-1). These results suggest that the acute
Charcot foot demonstrates excess osteoclastic activity without concomi
tant increase in osteoblastic function. This may be important in its p
athogenesis. (C) 1997 by John Wiley & Sons, Ltd.